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Abstract: Antiepileptic drug (AED) monotherapy is the preferred initial management approach in epilepsy care, since 
most patients may be successfully managed with the first or second monotherapy utilized. This article reviews the ration-
ale and evidence supporting preferential use of monotherapy when possible and guidelines for initiating and successfully 
employing AED monotherapy. Suggested approaches to consider when patients fail monotherapy include substituting a 
new AED monotherapy, initiating chronic maintenance AED polytherapy, or pursuit of non-pharmacologic treatments 
such as epilepsy surgery or vagus nerve stimulation. Reducing AED polytherapy to monotherapy frequently reduces the 
burden of adverse effects and may also improve seizure control. AED monotherapy remains the optimal approach for 
managing most patients with epilepsy. 
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INTRODUCTION 
  Epileptic seizures have been observed since antiquity 
[57].
  Treatment preferences generally favored polytherapy 
prior to the evolution of modern antiepileptic drugs (AEDs). 
In the early 1900s, phenobarbital and the ketogenic diet were 
used to manage epilepsy. Throughout the earlier 20
th century, 
the standard AEDs (phenytoin, phenobarbital, primidone, 
valproic acid, carbamazepine, and ethosuximide) were often 
combined in polytherapy use, due to the pervasive belief that 
polytherapy was more efficacious than monotherapy. How-
ever, during the 1970s, several studies suggested that mono-
therapy was equally efficacious, less toxic, and more toler-
able than polytherapy [51,52]. Since then, most epilepsy 
experts have advocated monotherapy as the preferred ap-
proach in epilepsy, although polytherapy is sometimes still 
necessary. This review examines the evidence favoring ini-
tial monotherapy and suggests methods to maintain mono-
therapy or reduce polytherapy to monotherapy when possi-
ble. 
THE RATIONALE FAVORING MONOTHERAPY 
  Since the early 1990s, the second-generation AEDs, fel-
bamate, gabapentin, lamotrigine, topiramate, tiagabine, ox-
carbazepine, levetiracetam, zonisamide, and pregabalin, have 
become available. Recently, the seemingly ever increasing 
armamentarium of AEDs has seen two additional newer 
(“third-generation”) AEDs released, lacosamide and rufina-
mide. Advantages of most newer AEDs include a more de-
sirable safety profile and fewer adverse effects and drug in-
teractions than their predecessors. Recent pivotal clinical 
trials have provided evidence to support monotherapy use of 
second-generation AEDs [42].
 Current treatment guidelines 
recommend monotherapy in most cases because data indicate  
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similar efficacy and better patient tolerability compared to 
polytherapy [43-45,48,49,51,52].
  Polytherapy may only 
minimally increase seizure control and can substantially in-
crease AED toxicity, [9,20,43-45,48,49,51,52] drug interac-
tions, [2,21,30,34,38,39,40,41] seizure aggravation [43,44],
 
comorbid depression,[39]
 risk of sudden unexplained death 
in epilepsy patients (SUDEP), [28,36,37] noncompliance, [8] 
and cost [4]. Polytherapy and seizure burden were the two 
main causes of quality of life impairment in one recent sur-
vey of epilepsy patients [58].
 
WHO BENEFITS MOST FROM MONOTHERAPY? 
  While monotherapy is preferable for most patients with 
epilepsy, monotherapy is particularly desirable for certain 
special patient populations, including women, elderly, and 
patients with co-morbid conditions (who are at increased risk 
for AED toxicity and drug interactions) [11,21,38]. Com-
pared to polytherapy, monotherapy reduces the potential for 
adverse drug interactions. Hepatic and renal dysfunction 
significantly impacts the metabolism and elimination of 
many AEDs, which may reduce tolerability and safety of 
continued use.
 Pregnant women taking two or more AEDs 
are at substantially increased risk of fetal malformations (3% 
versus 15%) than mothers receiving monotherapy [11].
 See 
Table 1 for a list of monotherapy recommendations.  
EVIDENCE SUPPORTING PREFERENTIAL MONO-
THERAPY IN EPILEPSY 
  The majority of patients with epilepsy respond to treat-
ment with monotherapy; 47% of patients become seizure-
free with the first AED tried, and another 13% achieve free-
dom from seizures with the second monotherapy trial [24].  
  While available evidence is central in determining 
whether an AED is effective for monotherapy usage, FDA 
approval and indication generally guide how an AED will be 
prescribed. First-generation AEDs were “grandfathered” by 
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seizure type without requirement to satisfy current rigorous 
approval requirements [42]. The majority of second-gene-
ration AEDs are approved only as adjunctive therapies. Cur-
rent FDA standards require superiority trial designs since 
placebo-controlled studies are considered unethical in epi-
lepsy, and few such studies have been conducted given the 
practical difficulties and expense involved in such trials [42].
 
United States practitioners are thus at the mercy of superior-
ity trial design data produced by trials that are conducted for 
the purpose of gaining FDA approval, a somewhat artificial 
circumstance leaving practitioners in doubt as to how to util-
ize the AED for monotherapy in clinical practice, unlike in 
Europe where approval standards permit the more practical 
standard of equivalence trial designs. As a result, many U.S. 
clinicians often continue to prescribe first-generation AEDs 
for new onset epilepsy because of experience and familiarity, 
limited comparative efficacy data with newer AEDs, and 
concern over the higher cost of newer drugs. To determine 
the best AED choices for monotherapy, further randomized, 
double-blind, long-term, comparative clinical trials with the 
newer AEDs are needed. Since few comparator studies are 
funded by industry, government agencies should become 
involved in conducting additional comparative clinical trial 
studies, and independent groups (ie, International League 
Against Epilepsy) should be persuaded to collect data from 
historically treated and control patients.  
  Currently, four second-generation AEDs are FDA ap-
proved for use as monotherapy, with some limitations; these 
are oxcarbazepine, lamotrigine, topiramate, and felbamate 
[17]. In four randomized, controlled, blinded trials, oxcar-
bazepine demonstrated efficacy as monotherapy in patients 
with partial seizures [36,60].
  Lamotrigine is currently ap-
proved as monotherapy when converting from an enzyme-
inducing AED or valproate but not for de novo or initial 
monotherapy [17]. However, lamotrigine should be used 
with caution in persons under the age of 16 due to a higher 
incidence of a potentially life-threatening rash in pediatric 
patients,
 [27]
 and patients receiving concurrent valproic acid 
or who receive inappropriately fast initial titration of lamo-
trigine are also at heightened risk of serious rash [34].
 Topi-
ramate is indicated as initial monotherapy in adults and chil-
dren aged 10 years and older with partial onset or primary 
generalized seizures; efficacy was established in both a large, 
double-blind, dose-controlled study and a second large trial 
comparing two doses of topiramate with standard compara-
tors carbamazepine and valproate [3,17,59].
 Felbamate also 
has evidence for monotherapy use in partial-onset seizures;
 
however, severe idiosyncratic toxicities limit its use [15,16].
 
Additionally, gabapentin possesses adequate evidence for 
confident use as monotherapy in treatment of partial-onset 
seizures, although it lacks formal FDA approval for this in-
dication [10,17].
  
  Among the second-generation AEDs approved for mono-
therapy use, few comparator trials have been conducted. 
Gabapentin and lamotrigine have been shown to be compa-
rably effective and tolerable in two large prospective trials, 
and were more tolerable than carbamazepine in elderly with 
newly diagnosed epilepsy [6]. A large, naturalistic, un-
blinded controlled trial recently demonstrated superior effi-
cacy (for time to treatment failure) of lamotrigine as com-
pared to carbamazepine, oxcarbazepine, and topiramate [31]. 
  The other second-generation and third-generation AEDs 
have not been FDA approved for monotherapy use since 
most lack an adequate level of evidence for this indication. 
However, the efficacy and tolerability of levetiracetam 
monotherapy for treatment of partial-onset seizures has been 
confirmed in a recent large, prospective, comparator trial 
against carbamazepine [7]. Small controlled clinical trials are 
also available to support tiagabine monotherapy use [47]. 
GUIDELINES FOR AED MONOTHERAPY 
  Given the complexity and expansive body of evidence 
concerning AED therapy in the medical literature and limita-
tions in practical application of this literature to actual pa-
tients, practice guidelines and expert surveys are valuable 
tools to assist clinicians in applying evidence based practice 
for patients with epilepsy. Practice guidelines are available to 
Table  1.  Monotherapy AED Options for Different Patient Populations: A Compilation of Practice Guidelines and Clinician   
Recommendations for the Treatment of Generalized Tonic-Clonic, Absence, Partial, and Myoclonic Seizures*
‡† 
Patient Characteristic  First Line  Supporting Reference 
Elderly  Lamotrigine or Levetiracetam  [26, 27] 
Female of reproductive age  Lamotrigine  [25-27] 
Pregnant Lamotrigine  [26,  27] 
Liver failure  Levetiracetam or Lamotrigine or Gabapentin
a  [26, 27] 
Renal failure  Lamotrigine or Valproic acid
b  [26, 27] 
Depression  Lamotrigine or Valproic acid
b or Oxcarbazepine
c  [26, 27] 
aAbsence seizures only. 
bGeneralized tonic-clonic seizures only. 
cSimple partial and secondarily generalized tonic-clonic seizures only.  
*Pregabalin not available at time of these studies. 
‡Topiramate not recommended in any of these patient groups by Karceski and colleagues [23]; however, French et al. [17] recommends topiramate as monotherapy.   
†French et al. [17]
 evaluated second-generation AEDs only. Antiepileptic Drug Monotherapy  Current Neuropharmacology, 2009, Vol. 7, No. 2    79 
assist practitioners in the management of new-onset and re-
fractory epilepsy and epilepsy in women. The American 
Academy of Neurology/American Epilepsy Society (AAN/ 
AES) Practice Guidelines for the treatment of new-onset 
epilepsy identified gabapentin, lamotrigine, oxcarbazepine, 
and topiramate as possessing Class I evidence (prospective 
study, blinding, statistical population-based sample, and pa-
tients studied concurrently and early in the course of therapy) 
for use as monotherapy in the treatment of new-onset partial 
or mixed seizures [18]. The recently updated guidelines for 
the treatment of epilepsy in women state that in women with 
epilepsy (WWE), monotherapy is recommended during the 
reproductive years to reduce the risk of teratogenicity seen 
with polytherapy [1]. 
  A recent survey of epilepsy experts found that lamo-
trigine, levetiracetam, and valproic acid are preferred AED 
choices for monotherapy in the treatment of generalized 
tonic-clonic, absence, and myoclonic seizures [23]. Previous 
survey results were compared to the current survey, and, 
overall, valproic acid is still the drug of choice for each of 
these seizure types, except for absence seizures, where etho-
suximide remains the preferred AED. Many practitioners 
chose lamotrigine and topiramate as first-line treatment for 
generalized tonic-clonic seizures.  
HOW TO INITIATE MONOTHERAPY 
  Practical tenets for achieving successful monotherapy in 
new-onset epilepsy management include the following: 1) 
select an efficacious AED for the specific seizure type; 2) 
choose an AED with a tolerable adverse effect and toxicity 
profile; and 3) titrate the AED slowly to the desired dose, 
taking into account the patient’s response to treatment. If the 
first AED monotherapy is ineffective, adding a second AED, 
then tapering and discontinuing the ineffective AED, is the 
preferred approach [56]. When switching AEDs, selecting an 
agent with a different MOA may increase the likelihood of a 
successful treatment response. If the second sequential AED 
monotherapy is ineffective, an adjunctive AED with a differ-
ent and potentially complementary MOA should be consid-
ered for use in adjunctive polytherapy. Since approximately 
35% of patients with epilepsy will not respond to monother-
apy, most refractory patients become candidates for poly-
therapy [24,26]. Polytherapy with lower or moderate dosages 
of two AEDs may also sometimes be preferred for manage-
ment of refractory patients who have dose-limiting neuro-
toxic adverse effects with high-dose monotherapy [24]. 
  Before initiating treatment, patients with epilepsy should 
undergo a thorough medical evaluation to determine seizure 
type and consider baseline patient characteristics that may 
influence the decision of whether treatment is necessary and, 
if so, which AED may be the most logical choice. Evaluation 
to determine the patient’s epilepsy syndrome begins with a 
thorough clinical history, including a detailed description of 
the seizure semiology, an awake and asleep electroencepha-
logram (EEG), and a brain magnetic resonance image (MRI). 
A standard brain MRI is adequate in newly diagnosed epi-
lepsy where the priority is to exclude underlying serious 
symptomatic pathologies, such as arteriovenous malforma-
tions or neoplasms. However, when feasible, available, and 
of reasonable cost, it is advantageous to consider obtaining 
brain MRI with a volumetric seizure-protocol study in pa-
tients with suspected partial-onset seizures, given better 
identification of subtle mesial temporal lobe pathologies 
such as hippocampal sclerosis or malformations of cortical 
development that may impact on prognosis for drug respon-
siveness, as well as future decisions regarding surgical triage 
if the patient becomes refractory to AEDs. 
  Educating the patient about epilepsy, AED compliance, 
and seizure first-aid is important for ensuring successful 
therapy. AED selection is determined by seizure type, patient 
medical history, and concurrent medications. For partial epi-
lepsy, any approved AED could be considered for use (ex-
cept ethosuximide, which is ineffective for partial-onset sei-
zure treatment). In idiopathic or symptomatic generalized 
epilepsies, as well as for ambiguous or unknown epilepsy 
syndromes, a broad-spectrum AED should be preferentially 
utilized given the potential to treat (or avoid aggravation of) 
other potentially associated generalized seizure-types in gen-
eralized epilepsies (i.e., absence and myoclonic seizures in 
idiopathic generalized epilepsies, or tonic seizures in symp-
tomatic generalized epilepsy). 
  Once an AED has been selected, starting with a low dose 
and gradually titrating to a moderate and presumably effec-
tive dose is a reasonable strategy, since titration to doses 
higher than a mean effective dosage are often poorly toler-
ated and only provide additional efficacy in perhaps 10% to 
15% of patients [24]. A more rapid titration may be neces-
sary in selected patients who have had multiple recent sei-
zures. Maximizing the dose is only recommended in patients 
who do not respond to moderate doses. At each patient visit, 
it is necessary to conduct a detailed assessment of AED ther-
apy, including adverse effects and compliance. Utilizing a 
quantitative survey of patient’s perceived adverse effects 
such as the adverse events profile (AEP) has been shown to 
improve physicians’ ability to detect adverse effects of 
treatment and appropriately alter antiepileptic drug therapies 
to improve quality of life [19]. The impact of adverse effects 
on daily living should be discussed, and any barriers to com-
pliance should be addressed. 
WHY ARE SOME PATIENTS REFRACTORY TO 
MONOTHERAPY? 
  The efficacy of currently available AEDs is limited to 
reduction of seizure frequency, and no AED has yet been 
proven to impact the pathophysiology of epilepsy itself [55]. 
Currently, there is no convincing evidence that any of the 
available AEDs are anti-epileptogenic, nor has any AED 
been shown to favorably impact the long-term outcome of 
epilepsy [24]. Yet, prescribing an AED after a second or 
third seizure event is the accepted practice standard, based 
on logic derived in part from epidemiologic studies of the 
natural history of new onset unprovoked seizures that con-
firm a greatly increased risk for further seizure recurrence 
following the occurrence of a second unprovoked seizure 
[22].
 The desired short-term outcomes of epilepsy manage-
ment are seizure freedom, seizure control when complete 
seizure freedom is not possible, and maximizing patient 
quality of life, given that the complications of untreated sei-
zure activity are increased risk of injury and mortality, cog-
nitive and behavioral abnormalities, and social disadvantage. 80    Current Neuropharmacology, 2009, Vol. 7, No. 2  Erik K. St. Louis 
Currently, there is no AED for the treatment of epilepsy that 
is completely effective, without adverse effects, and effica-
cious for all patients. Of the older AEDs, carbamazepine was 
shown to be the most effective and tolerable AED in two 
pivotal clinical trials; thus, it became the standard to which 
developing AEDs have been compared, [7,31-33]
 although 
carbamazepine itself has never been compared to placebo or 
demonstrated efficacy in an active control-designed study. 
Most studies have shown that newer AEDs have equivalent 
efficacy to that of carbamazepine, but several newer AEDs 
have superior tolerability including lamotrigine and gabapen-
tin [6,46]. However, recently published comparator trials of 
newer AEDs against a sustained release form of carba-
mazepine have shown relatively equivalent tolerability, sug-
gesting that immediate release forms of carbamazepine may 
be less tolerable and sustained release forms of carba-
mazepine are equally tolerable to newer AEDs [7,31].
  
WHY DOES MONOTHERAPY FAIL? 
  AED monotherapy may fail for a variety of reasons, in-
cluding errant diagnosis (eg, mistaking syncopal spells as 
seizures), inaccurate diagnosis of seizure type leading to 
ineffective AED choice (eg, mistaking partial complex sei-
zures for absence with prescription of carbamazepine rather 
than ethosuximide or valproate), intolerable adverse effects 
(eg, depression, sedation, cognition problems), idiosyncratic 
reactions (eg, rash, aplastic anemia, hepatoxicity), noncom-
pliance, over treatment,
  [50] and pharmacogenetic factors 
[53]. Monotherapy is most likely to be effective if the clini-
cian develops a personalized treatment plan that is appropri-
ately customized for the individual patient, provides the pa-
tient with suitable education concerning the drug chosen, and 
offers the opportunity for close telephone follow-up and sur-
veillance with evolution of any adverse effects to enable 
prompt feedback and modification of the titration scheme or 
target dose.  
  Monotherapy may be ineffective when the AED choice is 
suboptimal for a particular patient type.
  Certain AEDs are 
arguably best avoided in certain patient types, such as pheny-
toin or carbamazepine in the elderly
 [21,29] (given their vul-
nerability for adverse effects, osteoporosis, and drug interac-
tions) or valproate in women of child-bearing potential 
(given its heightened teratogenic risk) [11]. AEDs that re-
quire substantial hepatic metabolism are best avoided in pa-
tients with liver disease. Carbamazepine, phenytoin, pheno-
barbital, primidone, oxcarbazepine, and high-dose topiramate 
are enzyme inducers; these agents increase the hepatic me-
tabolism of concurrently administered drugs, endogenous 
and exogenous sex hormones, and vitamin D. Enzyme-
inducing AEDs can lead to: therapeutic failure of other in-
ducible AEDs and other drugs such as anticoagulants, hor-
monal contraceptives, lipid-lowering agents, and antihyper-
tensives; reproductive dysfunction; and osteopenia or frank 
osteoporosis [21,40,41]. Primidone and phenobarbital are not 
commonly recommended as first-line therapies due to poor 
tolerability and efficacy as well as abuse potential. Felba-
mate is associated with rare but potentially fatal idiosyncratic 
hematologic and hepatic toxicities, limiting its use solely to 
brittlely refractory patients [16].  
  Overtreatment may be another cause of failure [14]. Ap-
proximately 50% of patients with new onset epilepsy achieve 
remission with moderate doses of the first AED prescribed 
[26]. When a moderate dose fails, maximizing the dose re-
sults in up to 10-25% of patients obtaining seizure control,
 
[25] but at the risk of adverse events. Rarely, some epilepsy 
patients may experience a paradoxical increase in seizure 
frequency or severity at higher AED doses [54]. If no im-
provement or a worsening in seizure activity is seen, the 
AED dose should be reduced or the drug discontinued.  
WHAT TO DO WHEN MONOTHERAPY FAILS 
  Patients who do not achieve seizure freedom on an ap-
propriately selected and optimally administered initial AED 
monotherapy are unlikely to become seizure free on future 
AED trials [25]. If the patient is experiencing breakthrough 
seizures while receiving moderate doses of an AED, increas-
ing the dosage of that AED until the patient has either be-
come clinically toxic or has shown a clear plateau in re-
sponse to the medication is reasonable. If the patient has 
continued breakthrough seizures at this point, transition to a 
second monotherapy is indicated. Approximately two-thirds 
of epilepsy patients will have adequate seizure control with 
either the first or second trial of AED monotherapy [25]. The 
remaining third are considered to have refractory epilepsy.
 If 
a second monotherapy also fails, consideration of initiating 
AED polytherapy by adding a drug with a different and 
complementary principle mechanism of action should be 
considered. While monotherapy is preferable to polytherapy, 
some patients will require more than one AED to attain suc-
cessful seizure control [12,13]. In refractory patients receiv-
ing polytherapy, the treatment goal necessarily shifts some-
what from the goal of producing seizure freedom, which is 
increasingly improbable, to effecting palliation and control 
of seizures while minimizing adverse effects. Since refrac-
tory patients rarely attain seizure-freedom with polytherapy, 
many require evaluation for alternative non-pharmacologic 
treatments such as resection surgery or vagus nerve stimula-
tion (VNS).  
  Patients who subsequently become refractory to the first 
or second empiric AED monotherapy should be strongly 
considered for ictal seizure recording with video-EEG moni-
toring to ensure that the epilepsy diagnosis is accurate, and if 
so, to establish the correct epilepsy syndrome diagnosis. 
Video-EEG monitoring allows an accurate diagnosis of the 
seizure-type, which may enable the clinician to appropriately 
tailor AED therapy and explore the patient’s potential candi-
dacy for resection surgery or VNS therapy. Video-EEG 
monitoring also ensures exclusion of diagnoses that mimic 
epilepsy, such as psychogenic non-epileptic spells (ie, pseu-
doseizures), a particularly common finding representing be-
tween 30-50% of admissions to most epilepsy monitoring 
units. In such cases, AEDs may in most cases be tapered and 
discontinued, with referral to appropriate psychological 
counseling resources, and when necessary, psychiatric care. 
More rarely, physiologic non-epileptic spells such as syn-
cope or sleep disorders are instead identified in some patients 
with suspected epilepsy, and appropriate referral to other 
specialists can be offered. Antiepileptic Drug Monotherapy  Current Neuropharmacology, 2009, Vol. 7, No. 2    81 
CONVERTING FROM POLYTHERAPY TO MONO-
THERAPY 
  Patients may begin receiving polytherapy while transi-
tioning from one trial of monotherapy to another (transitional 
monotherapy), or because of two failed attempts with mono-
therapy (chronic polytherapy). In the first situation, eventual 
monotherapy is likely to result once the original AED is ta-
pered off. However, in the latter case, patients may continue 
on multiple AEDs indefinitely. While receiving multiple 
AEDs, some patients may go into seizure remission, while 
other patients will continue to require sequential trials of 
additional AEDs (AED sequencing). Patients who are appro-
priate candidates for tapering one or more AEDs are those 
who have been seizure free for 2 years or longer. For these 
patients, a slow taper is recommended, with dose reductions 
occurring weekly or every other week. Additionally, patients 
receiving unsuccessful polytherapy (ie, polytherapy that has 
failed to produce seizure freedom or that is resulting in intol-
erable adverse effects) should be considered for a further 
trial of monotherapy or additional AED sequencing.  
CONCLUSIONS  
  Epilepsy treatment often requires lifelong medication 
management. Monotherapy is preferred when managing pa-
tients with epilepsy, given similar efficacy and superior tol-
erability compared to polytherapy for most patients, espe-
cially those with newly diagnosed epilepsy who are not re-
fractory to other treatments. While preferred for initial use in 
epilepsy treatment, monotherapy may also fail for a variety 
of reasons. Monotherapy may fail in patients who do not 
receive thorough evaluation and counseling by their physi-
cian. Patients need to have a clear understanding of treatment 
expectations candidates for tapering of one or more AEDs. 
Adverse effects, noncompliance, and evolving refractory 
epilepsy are the principle reasons for treatment failure. To 
increase the likelihood of successful monotherapy, clinicians 
should consider individual patient characteristics, including 
seizure type, potential drug interactions, likelihood of com-
pliance, and cost, while realizing that therapy may require 
modification. Vigilance for need of further medication titra-
tion or tapering, the patient’s current seizure frequency and 
severity, and occurrence of adverse effects is necessary for 
successful monotherapy in epilepsy care. 
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